MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast.
美國康州丹伯裏和加州西湖村，2024年7月30日 (環球社交網)——曼恩凱德生物醫療公司(Nasdaq: MNKD)今日宣佈，將於2024年8月7日星期三美國股市開盤前公佈2024年第二季度業績。關於季度業績的新聞發佈會將於當天提前大約一個小時發出。
MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at . A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
曼恩凱德將於美國東部時間上午9:00爲投資者、媒體和公衆舉辦在線研討會。曼恩凱德公司將會議花紐約州立大學斯托尼布魯克分校市長學院出身的首席執行官Michael Castagna, PharmD和負責管理資金的臨時代碼Chris Prentiss。在線研討會將通過曼恩凱德的網站鏈接進行訪問，同時在會議結束後24小時內，可以在相同位置獲取重播，重播將可以獲取的時間大約90天。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凱德生物醫療公司（Nasdaq：MNKD）專注於爲那些患有內分泌和孤兒肺病的患者開發和商業化創新吸入治療產品和設備。
我們致力於利用我們的配方能力和設備工程的技術，減輕糖尿病，非結核分枝桿菌（NTM）肺病，肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉配方和吸入設備——可以快速，方便地向肺的深處輸送藥物，從而在目標疾病的治療方面產生局部或進入系統循環的作用，具體取決於治療目標。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我們致力於利用我們的配方能力和設備工程專業知識減輕糖尿病、非結核分枝桿菌（NTM）肺病、肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉製劑和吸入設備——爲藥物快速、便捷地輸送到深層肺部提供了可能，這些藥物可以在當地發揮功效，也可以進入系統循環，具體取決於治療指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凱德生物醫療的全國性合作團隊的熱情協作下，我們的使命是讓人們掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
請訪問mannkindcorp.com獲取更多信息，並在LinkedIn、Facebook、X或Instagram上關注我們。
Contact MannKind:
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
聯繫曼恩凱德:
投資者關係
(818) 661-5000
電子郵件：ir@mnkd.com
企業通訊
（818）292-3500
電子郵件：ir@mnkd.com
Source: MannKind
來源：曼恩凱德生物醫療